Amprenavir

Clinical data
Trade names	Agenerase
AHFS/Drugs.com	Monograph
MedlinePlus	a699051
License data	EU EMA: by INN US FDA: Amprenavir
Routes of administration	Oral (capsules)
ATC code	J05AE05 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	90%
Metabolism	Hepatic
Elimination half-life	7.1–10.6 hours
Excretion	<3% renal
Identifiers
IUPAC name (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate
CAS Number	161814-49-9 Y
PubChem CID	65016
DrugBank	DB00701 Y
ChemSpider	58532 Y
UNII	5S0W860XNR
KEGG	D00894 Y
ChEBI	CHEBI:40050 Y
ChEMBL	ChEMBL116 Y
NIAID ChemDB	006080
CompTox Dashboard (EPA)	DTXSID5046061
ECHA InfoCard	100.262.589
Chemical and physical data
Formula	C25H35N3O6S
Molar mass	505.63 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O[C@H]1CCOC1)N[C@@H](Cc2ccccc2)[C@H](O)CN(CC(C)C)S(=O)(=O)c3ccc(N)cc3
InChI InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 Y Key:YMARZQAQMVYCKC-OEMFJLHTSA-N Y
(verify)

Amprenavir (original brand name Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 (eight) very large 150 mg gel capsules or 24 (twenty-four) 50 mg gel capsules twice daily.^[1]

It was patented in 1992 and approved for medical use in 1999.^[2] Production of amprenavir was discontinued by the manufacturer on December 31, 2004; a prodrug version (fosamprenavir), is available.

Background

Research aimed at development of renin inhibitors as potential antihypertensive agents had led to the discovery of compounds that blocked the action of this peptide cleaving enzyme. The amino acid sequence cleaved by renin was found to be fortuitously the same as that required to produce the HIV peptide coat. Structure–activity studies on renin inhibitors proved to be of great value for developing HIV protease inhibitors. Incorporation of an amino alcohol moiety proved crucial to inhibitory activity for many of these agents. This unit is closely related to the one found in the statine, an unusual amino acid that forms part of the pepstatin, a fermentation product that inhibits protease enzymes.^{[citation needed]}